Bio Medica Laboratories IPO Details

SME NSE

Bio Medica Laboratories IPO Summary

Bio Medica Laboratories IPO opens for subscription on 21 May 2026 and closes on 25 May 2026.The IPO will be listed on NSE with the tentative listing date set for 29 May 2026.

Bio Medica Laboratories IPO price band has been fixed at ₹132 – ₹139 per share. The face value is ₹10 per share with a lot size of 1000.

Bio Medica Laboratories IPO total issue size comprises 37,72,000 shares (aggregating up to ₹52.43 Cr). This includes a fresh issue of 33,95,000 shares (aggregating up to ₹47.19 Cr). Offer for Sale consists of 3,77,000 shares (aggregating up to ₹5.24 Cr). Pre-issue shareholding stands at 91,80,001, which will increase to 1,25,75,001 post-issue.

Bio Medica Laboratories IPO carries a ₹-9 (-6.47%) GMP, reflecting investor sentiment.

Bio Medica Laboratories IPO Lot Size :Individual Minimum is 2 lots (2,000 shares) amounting to ₹278,000. Individual Maximum is 2 lots (2,000 shares) amounting to ₹278,000. SHNI Minimum is 3 lots (3,000 shares) amounting to ₹417,000. SHNI Maximum is 7 lots (7,000 shares) amounting to ₹973,000. BHNI Minimum is 8 lots (8,000 shares) amounting to ₹1,112,000.

The Lead Managers for Bio Medica Laboratories IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Narnolia Financial Services Ltd . To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.

For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is Prabhat Financial Services. You can analyze their track record by checking the Market Maker Performance Summary report.

For detailed information, Refer to the Bio Medica Laboratories Limited RHP.

Bio Medica Laboratories IPO Details

Listing Price : ₹111.2 at a Discount of 20%

Open Date

21 May 2026

Close Date

25 May 2026

Listing Date

29 May 2026

Issue Price

₹132 - ₹139

Face Value

₹10 per share

Lot Size

1000 Shares

GMP

₹-9(-6.47%)

Issue Type

IPO

Listing On

NSE

Type

Book Built Issue

Pre-issue Shareholding

91,80,001 shares

Post-issue Shareholding

1,25,75,001 shares

Total Issue Size

37,72,000 shares(aggregating up to ₹52.43 Cr)

Fresh Issue

33,95,000 shares(aggregating up to ₹47.19 Cr)

Offer for Sale

3,77,000 shares(aggregating up to ₹5.24 Cr)

Bio Medica Laboratories IPO Subscription

Bio Medica Laboratories IPO Application Wise Breakup

Bio Medica Laboratories IPO Dates

21 May 2026
Opening dateOpen
25 May 2026
Closing dateClose
26 May 2026
Allotment Date Allotment
27 May 2026
Initiation of RefundsRefund
27 May 2026
Credit of SharesCredit
29 May 2026
Listing dateListing

Bio Medica Laboratories IPO Lot Size

Application	Lots	Shares	Amount
Individual Minimum	2	2000	₹278,000
Individual Maximum	2	2000	₹278,000
SHNI Minimum	3	3000	₹417,000
SHNI Maximum	7	7000	₹973,000
BHNI Minimum	8	8000	₹1,112,000

Bio Medica Laboratories IPO Reservation

Promoter Holding

Pre Issue:

99.99%

Post Issue:

67.69%

Promoter Names:

Mr. Mukesh Mehta, Mr. Pradeep Mehta

Documents

DRHP

Bio Medica Laboratories IPO DRHP

RHP

Bio Medica Laboratories IPO RHP

Bio Medica Laboratories IPO Valuations

ROE54.41%

ROCE23.22%

Debt/Equity2.23

RoNW54.41%

PAT Margin30.35%

EBITDA Margin47.11%

EPS(₹) (Pre IPO)10.67

EPS(₹) (Post IPO)10.33

P/E (x) (Pre IPO)13.03

P/E (x) (Post IPO)13.45

Bio Medica Laboratories Financial Information

Period Ended	30 Nov 2025	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	65.17	39.12	19.53	17.57
Total Income	28.63	38.33	15.34	16.25
Profit After Tax	8.66	9.79	2.50	0.33
EBITDA	13.45	15.21	5.63	1.70
NET Worth	17.12	14.73	4.94	2.44
Reserves and Surplus	7.94	5.55	4.84	2.34
Total Borrowing	38.17	15.01	10.49	9.61
Amount in ₹ Crore

About Bio Medica Laboratories IPO

Incorporated in August 2015, Bio Medica Laboratories specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the-counter (OTC) medications in liquid and dry-powder injectable forms.der injectables. These injectables are available in both single-dose and multi-dose formats, serving the needs of both human and veterinary healthcare.

Product portfolio:

Liquid Injectables: 58 products are offered under this category
Dry powder injectables: 15 products under this category

It offers comprehensive range of products, including generic drugs, branded pharmaceuticals, over the counter (OTC) products, and other medications.

The company operates on a B2B model, focusing exclusively on contract manufacturing. It develop formulations for various companies in accordance with their specific requirements and product specifications. It is certified for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certificate issued by the Food & Drugs Administration, Madhya Pradesh.

It has two manufacturing facilities in Indore, Madhya Pradesh.

Strength Of Bio Medica Laboratories IPO

Designing and execution capabilities.
Experienced management team and a motivated and efficient work force.
Cordial relations with our consumers.
Quality assurance and control.

Risk Of Bio Medica Laboratories IPO

The company is dependents on a limited number of clients for a significant portion of its revenues, and the loss of any key client could adversely affect the company's business, financial condition and results of operations.
Any manufacturing or quality control problems may damage the company's reputation for high quality products and expose the company to litigation or other liabilities, which could adversely affect its financial results.
The company's inability to adopt new technologies could adversely affect its business, results of operations, cash flows and financial condition.
The operations in the company's Manufacturing Unit-1 had been suspended vide order No. V/T/MISC/20/2023/4790 dated August 23, 2023 by the Deputy Director and State Licensing Authority, Food and Drug Administration, Madhya Pradesh citing certain non-compliances
The company is dependents on third-party transportation providers for the supply of raw materials and finished products.
The Company has negative cash flows from its investment and financing activities in the current and past years. Sustained negative cash flow could have an impact on its growth and business.
The Contracts in our order book may be adjusted, cancelled, or suspended by its clients at their discretion, and therefore the company's order book is not necessarily indicative of future revenues or earnings.
The company's existing manufacturing facilities are concentrated in a single region i.e., Industrial Area, Indore, Madhya Pradesh and the inability to operate and grow its business in this particular region may have an adverse effect on the company's business, financial condition, results of operations, cash flows and future business prospects.
The Company does not own the premises through which the company conduct its business operations.
The risks associated with delays in obtaining, or failures to obtain, approvals and permits for the building plan of the company's proposed manufacturing facility.

Objectives Bio Medica Laboratories IPO

1. Repayment of Loan

2. Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises

3. General Corporate Purposes

Company Contact Details

Bio Medica Laboratories Ltd.
Plot No. 11B-11C, Sector-E, Sanwer Road
Industrial Area, Industrial Estate (Indore),
Indore, Madhya Pradesh, 452015
Phone: +91 7314102751
Email: companysecretary@biomedica.co.in
Website: http://www.biomedica.co.in/

Registrar Contact Details

Name:

Skyline Financial Services Pvt Ltd

Phone:

+91-22-28511022

Email:

ipo@skylinerta.com

Website:

https://www.skylinerta.com/ipo.php

Lead Mangers

Market Maker

Bio Medica Laboratories FAQs

The Bio Medica Laboratories IPO is a SME public issue comprising 3772000 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹52.43 Cr. The issue price has been fixed at ₹139 per equity share, and the minimum application size is 1000 shares.

The IPO opens for subscription on 21 May 2026, and closes on 25 May 2026.

Skyline Financial Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the NSE

The Bio Medica Laboratories IPO opens on 21 May 2026.

Bio Medica Laboratories IPO lot size is 1000, and the minimum amount required for application is ₹139000.

You may apply for the Bio Medica Laboratories IPO online by using either the UPI or ASBA payment method. The ASBA facility is available through the net banking platform of your respective bank. The UPI-based IPO application option is typically provided by brokers that do not offer banking services. For detailed guidance on the online IPO application process, please refer to the procedures outlined by Zerodha, Groww, Upstox, 5Paisa, Paytm Money, Fyers, Alice Blue, Nuvama, HDFC Bank, ICICI Direct, Kotak Securities, Axis Direct, and SBI Bank.

The Basis of Allotment for the Bio Medica Laboratories IPO is scheduled to be finalized on 26 May 2026. Subsequently, the shares allotted will be credited to investors’ demat accounts by 27 May 2026. Investors are advised to regularly check the Bio Medica Laboratories IPO allotment status for updates.

The listing date for the Bio Medica Laboratories IPO has not yet been officially announced. However, the tentative listing date is scheduled for 29 May 2026.

Bio Medica Laboratories IPO Grey Market Premium (GMP) refers to the unofficial price at which the company’s IPO shares are traded in the grey market prior to their listing on the stock exchange. The GMP serves as an indicator of investor demand, expected listing gains, and the overall market sentiment toward the IPO.

As of now, the current GMP stands at ₹-9 (-6.47%).